The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis

Breast Cancer Research

Volumn 8, Issue 3, 2006, Pages

  Cleator, Susan J ^a,b   Powles, Trevor J ^c   Dexter, Tim ^a   Fulford, Laura ^a   Mackay, Alan ^a   Smith, Ian E ^d   Valgeirsson, Haukur ^a   Ashworth, Alan ^a   Dowsett, Mitch ^a,d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c Parkside Hospital   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DOXORUBICIN; ANTINEOPLASTIC AGENT;

ACCURACY; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CELL COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DRUG RESPONSE; ERROR; FEMALE; FROZEN SECTION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; OUTCOMES RESEARCH; PREDICTION; REGRESSION ANALYSIS; STROMA CELL; UNINDEXED SEQUENCE; VALIDATION STUDY; ADJUVANT THERAPY; BIOPSY; BREAST NEOPLASMS; CLINICAL TRIAL; GENETICS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DNA, COMPLEMENTARY; DOXORUBICIN; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STROMAL CELLS; TREATMENT OUTCOME;

EID: 33745445353     PISSN: 1465542X     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1506     Document Type: Article

References (40)

1. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
2. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005, 23:2716-2725.
3. Cleator S, Ashworth A: Molecular profiling of breast cancer: clinical implications. Br J Cancer 2004, 90:1120-1124.
4. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483-2493.
5. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001:96-102.
6. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398.
7. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
8. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al.: A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
9. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
10. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, et al.: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004, 22:2284-2293.
11. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, et al.: Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004, 64:8558-8565.
12. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362:362-369.
13. Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares FA, Oliveira CT, et al.: Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005, 11:7434-7443.
14. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ: Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005, 23:3331-3342.
15. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005, 23:422-431.
16. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H: Predictors of primary breast cancers responsiveness to preoperative epirubicin/ cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J Transl Med 2005, 3:32.
17. WHO: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Genital Organs Lyon: IARC Press; 2003.
18. Cleator S, Makris A, Ashley SE, Lal R, Powles TJ: Good clinical response of breast cancers to neoadjuvant chemoendocrine treatment is associated with improved overall survival. Ann Oncol 2005, 16:267-272.
19. Ellis M, Davis N, Coop A, Liu M, Schumaker L, Lee RY, Srikanchana R, Russell CG, Singh B, Miller WR, et al.: Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res 2002, 8:1155-1166.
20. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001, 61:5979-5984.
21. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET: Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 2002, 4:R3.
22. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks JR, Nevins JR: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001, 98:11462-11467.
23. Dudoit S: Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments. Statistica Sinica 2002, 12:111-139.
24. Everitt BS: Cluster Analysis London: Arnold; 1993.
25. Lance G, Williams W: A general theory of classificatory sorting strategies: Hierarchical systems. Computer Journal 1967, 9:373-380.
26. Dudoit S, Fridlyand J: Classification in microarray experiments. In Statistical Analysis of Gene Expression Data Edited by: Speed T. Boca Raton: Chapman and Hall/CRC; 2003.
27. Wilcox R: Introduction to Robust Estimation and Hypothesis Testing San Diego: Academic Press; 1997.
28. Radmacher MD, McShane LM, Simon R: A paradigm for class prediction using gene expression profiles. J Comput Biol 2002, 9:505-511.
29. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121.
30. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al.: Gene expression patterns of breast carcinomas distinguish tumor sub-classes with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
31. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
32. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al.: Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
33. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR Jr, Elkahloun AG: In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999, 59:5656-5661.
34. Iacobuzio-Donahue CA, Argani P, Hempen PM, Jones J, Kern SE: The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res 2002, 62:5351-5357.
35. Lindsay CK, Thorgeirsson UP, Tsuda H, Hirohashi S: Expression of tissue inhibitor of metalloproteinase-1 and type IV collagenase/gelatinase messenger RNAs in human breast cancer. Hum Pathol 1997, 28:359-366.
36. Zhang F, Riley J, Gant TW: Intrinsic multidrug class 1 and 2 gene expression and localization in rat and human mammary tumors. Lab Invest 1996, 75:413-426.
37. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC: Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004, 113:1318-1327.
38. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:727-741.
39. Chen B, Nelson DM, Sadovsky Y: N-myc down-regulated gene 1 modulates the response of term human trophoblasts to hypoxic injury. J Biol Chem 2006, 281:2764-2772.
40. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, Chang JC: Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Res Treat 2006, 95:229-233.